Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK1043702 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | 14 days dosing |
| Cohort 2 | EXPERIMENTAL | Single dose followed by 14 days repeat dosing |
| Cohort 3 | EXPERIMENTAL | Up to 28 days repeat dosing with drug interaction |
| Name | Type | Description |
|---|---|---|
| GSK1043702 | DRUG | Oral dose in liquid or tablet formulation |
| Dextromethorphan | DRUG | 30mg Oral dose |
| Placebo | DRUG | To match GSK1034702 |
Inclusion Criteria: * Male or female of non childbearing potential * Generally healthy * Body mass index 19 - 29.9 kg/m2 (inclusive), body weight greater than or equal to 50 kg for males and greater than of equal to 45 kg for females * Normal Laboratory test results Exclusion Criteria: * Abuse of...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Alto Neuroscience, Inc. | ANRO | 1 | PHASE2 | ALTO-101 |
| Eli Lilly and Company | LLY | 2 | - | Undisclosed |
| Rhythm Pharmaceuticals, Inc. | RYTM | 1 | - | Undisclosed |
GSK1043702 is an investigational small molecule being developed for cognitive disorders. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being studied for its potential effects on cognitive function, though its exact mechanism of action has not been disclosed.
GSK1043702 is being developed by GSK plc, a global biopharmaceutical company. GSK plc is listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug for cognitive disorders.
GSK1043702 is in Phase 1 clinical development. This early-stage trial is designed to assess the safety, blood levels, and potential drug interactions of the compound. The Phase 1 study has been completed, and the drug remains investigational, meaning it has not received approval from regulatory agencies.
GSK1043702 has one completed Phase 1 clinical trial registered under NCT00950586. This study, titled 'Safety, Blood Levels, Drug Interaction and Effects of Repeated Doses of GSK1034702,' enrolled 48 participants in the United Kingdom. The trial was randomized, double-blind, and controlled, and it included healthy volunteers aged 18 years and older.
Yes, GSK1043702 is also known as GSK1034702. The clinical trial NCT00950586 uses the name GSK1034702 in its title, while the drug is referred to as GSK1043702 in other contexts. Both names refer to the same investigational compound being developed for cognitive disorders.